<?xml version="1.0" encoding="UTF-8"?>
<p id="p0065">Oseltamivir, a neuraminidase inhibitor, is frequently prescribed for the treatment of Influenza. It was prescribed to treat flu-like symptoms in COVID-19 patients at the onset of the outbreak in China before SARS-CoV-2 was identified as the etiologic factor. It has no scientific basis for the treatment of COVID-19 as viruses of the 
 <italic>Coronaviridae</italic> family do not utilize the enzyme neuraminidase. Moreover, Oseltamivir does not exhibit in-vitro activity against SARS-CoV 
 <xref rid="b0250" ref-type="bibr">[50]</xref>. Eighteen studies are currently listed for testing the drug on COVID-19 patients. Oseltamivir was shown to be ineffective in the treatment of COVID-19 by an in silico assessment, which also included an in vitro and retrospective study 
 <xref rid="b0255" ref-type="bibr">[51]</xref>.
</p>
